108results about How to "Reduce the number of cells" patented technology

Disclosed are agents (e.g., peptides, polypeptides, proteins, small molecules, antibodies, and antibody fragments that target senescent cells) and methods of their use for imaging senescent cells in vivo and for treating or preventing cancer, age-related disease, tobacco-related disease, or other diseases and disorders related to or caused by cellular senescence in a mammal. The methods include administering one or more of the agents of the invention to a mammal, e.g., a human. The agents, which specifically bind to senescent cells, can be labeled with a radioactive label or a therapeutic label, e.g., a cytotoxic agent.

A method of treating or preventing atherosclerosis in a mammalian subject comprises: (a) extracting the aliquot of blood from the subject; (b) treating the aliquot of blood ex vivo with at least one stressor selected from the group consisting of an oxidizing agent, ultraviolet radiation and elevated temperature; and (c) administering the aliquot of blood treated in step (b) to the subject. Preferably, the aliquot has a volume of from about 0.01 ml to about 400 ml and is treated simultaneously by ozone gas and ultraviolet radiation at a temperature of from 37-55° C.

The present invention relates to reporting cell measurement results associated with a plurality of cells of a cellular communication system. The reporting is transmitted from a station via a radio interface to receiver element of a cell serving the station. The cells are arranged in a reporting order that is to be used by the station for the reporting. The cell measurements are performed by the transceiver station for getting cell measurement results associated with a number of the cells. Relevant cell measurement results are then selected and the selected results are transmitted in the defined reporting order.

There is provided the use of a methylxanthine derivative such as theophylline and a steroid in a synergistic combination for the treatment of chronic obstructive pulmonary disease, wherein the combination is administered by the inhaled route for pulmonary delivery.

There is provided the use of a methylxanthine compound and a steroid in a synergistic combination for the treatment of a respiratory disease, wherein the methylxanthine compound is administered at a dose, which, in isolation, is not effective to treat said disease.

Reflex sympathetic dystrophy in a human patient is treated by collecting an aliquot of the patient's blood (e.g. 10 cc in volume), and subjecting it simultaneously to ozone/oxygen mixture and ultraviolet light, at a predetermined, elevated (e.g. 42.5 DEG C.) temperature, for approximately 3 minutes. After cooling, the treated blood aliquot is reinjected into the patient via the gluteal muscle. Reflex sympathetic dystrophy is alleviated following a course of such treatments.

An isolated binding partner of a Cripto-1 protein, Pim-1 protein or an antigen present in a colon cancer cell lysate is described. The binding partner inhibits growth of one or more cancer cell types and may be used in an anti-cancer agent for treating cancer in a subject. The binding partner may also be used in a method of inducing apoptosis in a cancer cell, as well as in a method of sensitising a cancer cell to a cytotoxic compound. In addition, a cancer Vaccine is described wherein the vaccine comprises a Cripto-1 protein (or an antigenic fragment thereof), Pim-1 protein (or an antigenic fragment thereof) or an antigen present in a colon cancer cell lysate or, alternatively, comprises an expressible DNA molecule encoding a Cripto-1 protein (or an antigenic fragment thereof), Pim-1 protein (or an antigenic fragment thereof) or an antigen present in a colon cancer cell lysate.

A method for distributing wireless resource in multicarrier time division duplexing mobile communication system, such as TD-CDMA system, to overcome the shortage of 3GPP single carrier cell channel distribution technology of covering more lager area in composing cellular system, which contains using an area of covering same or almost same as a cell, selecting one carrier as main carrier and other carriers as auxiliary carrier, the frequency of main carrier is as different as possible, setting all public control channel in main carrier, the left resource of main carrier and resource of auxiliary carrier are used in uplink and downlink service channel, the arrangement of public channel in main carrier is same with that in single carrier cell.

The present invention relates to the use of Fibroblast Growth Factor Receptor I (FGFR1) extracellular domain (ECD) polypeptides for treatment of cancers characterized by ligand dependent activating mutations in Fibroblast Growth Factor Receptor 2 (FGFR2). For example, the present invention relates to the treatment of endometrial cancers and other cancers wherein tumor cells express FGFR2 mutants in the IgII-IgIII hinge region or IgIII domain of the protein, such as at amino acid positions 252 and/or 253.

The invention discloses a handover measurement control method for a mobile communication system. In the method, by virtue of architectural characteristic of a TD-SCDMA (Time Division-Synchronous Code Division Multiple Access) system, RNCs (Radio Network Controllers) can carry out information interaction via an Iur interface or a core network (CN) and maintain a neighboring cell information list in real time; and according to the maintained neighboring cell information list, the RNCs only configure the cells with light load, small interference and good link quality in the neighboring cell information list in a measurement control message issued to UE (User Equipment), while the cells with severe or worse information are not used as measuring objects of the UE so as to prevent the cells with insufficient available resource, too big interference or poor communication link quality from being used as the measuring objects, which decreases number of the cells measured by the UE, reduces measuring burden of the UE, lowers time cost during the measuring process, realizes prior optimization for a measuring object list of the UE to a certain degree and reduces trial times during the handover process so as to reduce handover delay and drop call rate during the handover process and improve handover success rate.

The present application relates to compositions of chimeric anti-endoglin antibodies and anti-VEGF agents. Another aspect relates to the use of chimeric anti-endoglin antibodies and Bevacizumab. Another aspect relates to the use of the compositions to inhibit VEGF induced sprouting. Another aspect relates to the use of the compositions to inhibit angiogenesis.

An apparatus is provided, which monitors an operation state of a battery composed of a plurality of cells mutually connected in series. In this apparatus, a cell voltage of each of the plurality of cells is detected as information indicating an operation state of the battery. Based on the detected cell voltages, an operation state is monitored for a cell having a highest cell voltage and a cell having a lowest cell voltage among the plurality of cells.

Provided are an apparatus and a method for driving a self-emission display panel. A sustain pulse (STP) controller calculates an automatic power control (APC) level of image data having an input grayscale and outputs a STP corresponding to the calculated APC level. A sub-field (SF) controller which applies a dithering method to each SF corresponding to the input grayscale to generate SF data for expressing the input grayscale so as to reduce the number of cells simultaneously emitting light in a SF. A sustain/scan driver generates sustain/scan pulses from the output STP to drive the self-emission display panel. An address electrode driver generates an address driving signal corresponding to the input grayscale from the generated SF data to drive the self-emission display panel.

A fuel cell power supply device can include a fuel cell, a voltage boosting device with an input unit connected to the fuel cell, and an output unit connected to a first load. The boosting device can boost an output voltage and supply electric power to the first load. A storage device is connected to the input unit or the output unit, and a secondary battery can be connected to the output unit of the voltage boosting device via a voltage conversion device. An electric power supply control device controls operation of the voltage conversation device, to carry out supply of electric power to the first load from the secondary battery via the voltage conversion unit. The electric power supply control device also carries out charging of the secondary battery by the supply of electric power to the secondary battery from the voltage boosting device via the voltage conversion device.

Disclosed herein is a pharmaceutical composition having preventative and therapeutic effects on liver diseases, comprising an extract from Lonicera caerulea L. var. edulis. The composition has preventative and therapeutic effects on hepatitis, liver cirrhosis, fatty liver, and the like.

The present invention provides a new wine yeast product in a frozen form. The product is produced in a fermenter, concentrated, cryoprotectants are added. This mixture is then frozen at −50° C. What makes this product unique is that besides the fact that it is frozen, it can be directly added to grape juice as no rehydration is required because the yeast was not dehydrated in the production process.